ClinicaliQ Trial Snapshot
- OLE Study With Filgotinib in JIA — Recruiting • Phase III • Rheumatology • NCT07553182.
- Filgotinib appears safe and effective for long-term use in children with polyarticular or systemic juvenile idiopathic arthritis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period/prolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement. Conditions: Juvenile Idiopathic Arthritis (JIA) Interventions: Filgotinib Lead Sponsor: Alfasigma S.p.A. Planned Enrollment: 80 participants